Enrollment into Ph 1 study of EPI-7386 with apalutamide/abiraterone acetate plus prednisone in metastatic CRPC patients suspended due to operational recruitment challenges November 16, 2022
TRITON3 Ph 3 Trial Of Rubraca Achieves Primary Endpoint In Men With metastatic CRPC With BRCA Or ATM Mutations October 12, 2022
Ph 3 TALAPRO-2 study of TALZENNA® + XTANDI® in metastatic CRPC patients met primary endpoint of rPFS vs placebo plus XTANDI October 12, 2022
Detailed Results from Ph 3 COSMIC-313 Pivotal Trial in Patients with 1L RCC announced September 13, 2022
Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA and PADCEV as Monotherapy in 1L Advanced Urothelial Cancer September 13, 2022
Modi-1 Ph 1/2 trial open for recruitment in patients with TNBC, ovarian cancer, head and neck cancer, and RCC April 12, 2022
First Patient Treated in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract Urothelial Cancer April 21, 2021
